Pre and post-menopausal women with locally advanced or metastatic HR+/HER2-negative endocrine resistant breast cancer research hub

Targeting non-Luminal disease by PAM50 with pembrolizumab + paclitaxel in Hormone Receptor-positive/HER2-negative advanced/metastatic breast cancer, who have progressed on or after CDK 4/6 inhibitor treatment (TATEN trial)

This study looks at a new treatment called pembrolizumab combined with paclitaxel for some women with advanced breast cancer. It's for those whose cancer has grown even after previous treatments. Researchers want to see how well it shrinks tumours.